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Abstract 
Microtubule-associated protein tau is abnormally hyperphosphorylated and forms the major protein subunit of paired helical filaments (PHF) in 
Alzheimer disease brains. The abnormally phosphorylated sites Ser-199, Ser-202, Ser-396 and Ser-404 but not Ser-46 and Ser-235 of Alzheimer tau 
were found to be dephosphorylated by protein phosphatase-1 and this dephosphorylation was activated by Mn*‘. In contrast, protein phosphatase-2C 
did not dephosphorylate any of these sites. Both protein phosphatase-1 and -2C had high activities towards [“P]tau phosphorylated by CAMP- 
dependent protein kinase. These results suggest that both protein phosphatase-1 and -2C might be associated with normal phosphorylation state of 
tau, but only the former and not the latter phosphatase is involved in its abnormal phosphorylation in Alzheimer disease. 
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1. Introduction 
Microtubule-associated protein tau is a family of poly- 
peptides of apparent molecular weight 50,000 to 64,000 
Da that are the products of alternate splicing of a single 
gene [1,2]. Tau promotes the assembly of tubulin into 
microtubules and stabilizes their structure. Tau is a 
phosphoprotein and phosphorylation regulates its mi- 
crotubule assembly promoting activity [3]. Recently, 
more research interest has been focused on tau phospho- 
rylation because abnormally hyperphosphorylated tau 
has been proven to be the main protein component of 
paired helical filaments (PHF) which is one of the most 
characteristic cellular and molecular changes in Alz- 
heimer disease (AD) brain [4]. PHF-tau and in vitro 
phosphorylated tau have lower activity to stimulate mi- 
crotubule assembly as compared to normal tau, while 
dephosphorylation of PHF-tau by alkaline phosphatase 
can recover this activity [5,6]. 
Tau normally contains 2-3 mol of phosphate per mol 
of the protein, whereas it contains 5-9 mol of phos- 
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phate per mole of the protein in AD brain [7-91. So far 
nine abnormal phosphorylation sites of PHF-tau have 
been identified which are not phosphorylated in normal 
adult brain. They are Ser-46 [lo], Thr-123 [ll], Ser-199 
[4,12,13], Ser-202 [4,12,13], Thr-231 [14], Ser-235 [14,15], 
Ser-262 [14], Ser-396 [15,16], and Ser-404 [17] as num- 
bered according to the largest isoform of human tau, 
tau,, [2]. It seems there is a disfunction of tau phospho- 
rylation/dephosphorylation system which leads to the 
abnormal hyperphosphorylation of tau in AD brain. 
Therefore, it is of great interest to identify the protein 
kinases and protein phosphatases which are involved in 
the reversible process of tau phosphorylation. 
Phosphoseryl and phosphothreonyl protein phos- 
phatases (PP) have been classified by Cohen and In- 
gebritsen into four main types, i.e. PP-1, PP-2A, PP-2B 
and PP-2C [18]. These protein phosphatases are present 
in significant concentrations in human brain [19]. PP-2A 
and PP-2B have been shown to dephosphorylate tau 
phosphorylated by Ca”/calmodulin-dependent protein 
kinase and CAMP-dependent protein kinase (PKA) 
[20,21]. Recently, we found that PP-2A (Gong et al., 
manuscript submitted for publication) and PP-2B [22] 
also dephosphorylate Alzheimer tau at the abnormal 
phosphorylation sites. In this study, we describe the ac- 
tivities of the other two types of protein phosphatases, 
PP-1 and PP- 2C, towards tau phosphorylated by PKA 
and Alzheimer disease abnormally phosphorylated tau 
(AD P-tau). 
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2. Materials and methods 
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3. Results 
1.1. Materials 
Phosphorylase kinase was purified from rabbit skeletal muscle by the 
method of Cohen [23]. PKA was purchased from Sigma, St. Louis, MO, 
USA. Rabbit skeletal muscle PP-1 was purchased from Upstate Bio- 
technology Inc., Lake Placid, NY. PP-2B (holoenzyme) was purified 
from bovine brain according to the method of Sharma et al. [24]. PP-2C 
was purified from bovine kidney as described previously [25]. Polyclo- 
nal antibodies 102~ were raised as previously reported [lo]. Monoclonal 
antibodies Tau-1 and PHF-1 were kindly provided by Drs. L.I. Binder 
[26] and S. Greenberg [27], respectively; SM133, SM131, goat anti- 
mouse IgG and peroxidase-anti-peroxidase complex were purchased 
from Sternberger Monoclonals Inc., Baltimore, MD. Alkaline phos- 
phatase-conjugated goat anti-mouse and anti-rabbit IgG were pur- 
chased from Bio-Rad, Hercules, CA. 
17.2. Isolation of tau 
AD P-tau and normal human tau were isolated from autopsied brains 
of a 70-year-old male with Alzheimer disease and a 51-year-old male 
normal case, respectively [9]. Briefly, AD P-tau was isolated from a 
non-neurofibrillary tangle pool, the 27,000 x g to 200,000 x g fraction 
of the Alzheimer brain homogenate by extraction in 8 M urea, followed 
by dialysis against Tris buffer. This AD P-tau enriched fraction is 
readily soluble in buffer and abnormally phosphorylated as PHF-tau 
[9]. Normal human tau was purified from the 3545% ammonium 
sulfate precipitates of 200,000 x g brain supernatant, followed by acid 
treatment (PH 2.7) and chromatography on a phosphocellulose column 
(Cellulose Phosphate Pl 1, Whatman). 
2.3. Preparation of f’P]phosphorylase kinase and determination of 
protein phosphatase activities 
[“P]Phosphorylase kinase (1.9 mol “P incorporated/335,000 x g) 
phosphorylated by PKA was prepared as reported previously [19]. The 
activities of PP-1, PP-2B and PP-SC were measured by counting the 
radioactivitv released from l’*Plsubstrate as nreviouslv described 1191. 
The reaction mixtures contained 50 mM Tris, pH 7.0,2i) mMg-me&a;- 
toethanol, 1.0 mM MnCl, and 1.0 pM [‘*P]phosphorylase kinase for 
PP-1. For PP-2B and PP-2C activities, MnCl, was substituted by 1.0 
mM CaCl, and 1.0 PM calmodulin, and 10 mM MgCl,, respectively. 
One unit of protein phosphatase activity is defined as that amount 
which catalyzes the release of 1.0 nmol phosphate per min from 
[32P]phosphorylase kinase at 30°C. 
2.4. Treatment of AD P-tau with protein phosphatases 
Unless otherwise stated, dephosphorylation of AD P-tau was carried 
out at 30°C in 50 mM Tris, pH 7.0, 10 mM /I-mercaptoethanol, 0.1 
mg/ml BSA, 50 &ml AD P-tau and PP-1, PP-2B or PP-2C. In some 
experiments, several effecters were added in the reaction mixture (see 
section 3). The reaction was started by addition of the enzyme. After 
appropriate incubation times (see figure legends), reactions were 
stopped by addition of 5 volumes of cold acetone to precipitate pro- 
teins. The precipitated protein samples were dissolved in SDS-PAGE 
samule buffer and heated at 95°C for 4 min. followed bv 10% SDS- 
PAGE. Immunoblotting was carried out as described previously [4]. 
The primary antibodies for immunoblotting and their epitopes have all 
been previously characterized. They are phosphorylation-dependent as 
well as site-specific. Briefly, antibodies 102~ [lo], Tau-1 [4,12,13] and 
SM133 [15] recognize dephosphorylated form of tau at sites Ser-46, 
Ser-199/Ser-202 and Ser-235, respectively. Antibodies SM131 [15] and 
PHF-1 [28] recognize tau phosphorylated at Ser-396/Ser-404 and Ser- 
396, respectively. These antibodies were used at dilutions of 0.4 pg/ml 
for 102c, 1:lOO for SM131, 1:500 for SM133 and PHF-1, and 1:500,000 
for Tau-1. 
2.5. Preparation of [“‘P]tau and dephosphorylation of [“P]tau by 
protein phosphatases 
Tau purified from normal human brain was phosphorylated with 
[32P]ATP by PKA as described by Scott et al. [29]. About 2 mol ‘*P/m01 
tau was incorporated by PKA. Dephosphorylation of [3ZP]tau by PP-1, 
PP-2B and PP-2C was carried out employing the same conditions as 
those described above for the dephosphorylation of AD P-tau. The 
phosphatase activities were measured by counting the radioactivity 
released from [‘*P]tau as previously described [19]. 
3.1. Dejinition of PP-1 and PP-2C activities and their 
modulation by M$+ and M$’ 
To observe and compare the potential dephosphoryla- 
tion of AD P-tau by various protein phosphatases, the 
same amount of enzyme activity of each phosphatase 
should be used. Hence we employed [32P]phosphorylase 
kinase as a substrate to standardize the activities of PP-1 
and PP-2C. PP-1 and PP-2C activities are modulated by 
cations and each enzyme preparation responds differ- 
ently to divalent cations [30]. We therefore determined 
PP-1 and PP-2C activities in the absence and presence of 
either Mn*’ or Mg2’ using [32P]phosphorylase kinase as 
a substrate. As shown in Fig. 1, PP-1 was activated by 
1.0 mM Mn*+ but inhibited by 10 mM M$‘. PP-2C was 
Mg*+-or Mn*‘-dependent, and no activity was detected 
in the absence of Mg*+ or Mn2’. Highest activities were 
obtained using 1 .O mM Mn” for PP-1 and 10 mM M$ 
for PP-2C. Hence these conditions were used to study the 
in vitro dephosphorylation of AD P-tau and PKA- 
phosphorylated tau. 
3.2. Treatment of AD P-tau with PP-1 and PP-2C 
We have previously found that PP-2A dephos- 
phorylated abnormal phosphorylation sites Ser-46, 
Ser-199, Ser-202, Ser-396 and Ser-404 of AD P-tau 
(Gong et al., manuscript submitted for publication), and 
- 8 
% 
x 
E 4 
8 
IX 0 w 
Ob 60 
Time (min) 
Fig. 1. PP-1 (upper panel) and PP-2C (lower panel) activities in the 
presence or absence of various divalent metal ions. Dephosphorylation 
reactions were carried out using [“Plphosphorylase kinase as substrate 
as described in section 2, and in the presence of 1.0 mM EDTA (a, 
1 .O mM MnCl, (r) or 10 mM MgCl, (m). The open circles (0) indicate 
assays in the absence of the protein phosphatases. 
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Fig. 2. Dephosphorylation of AD P-tau by PP-1, PP-2B and PP-2C. Immunoblots of AD P-tau were carried out after incubation either without (lane 
1) or with 2.0 units/ml PP-1 (lane 2), PP-2B (lane 3) or PP-2C (lane 4) at 30°C for 60 min as described in Materials and Methods; lane 5 shows untreated 
normal human tau for comparison. Reaction mixtures for PP-1 and PP-2C also contained 1 .O mM MnCI, and 10 mM MgCI,, respectively. For PP-2B, 
1 .O PM calmodulin, 1 .O mM CaCl, and 1 .O mM MnCl, were included. Five phosphorylation-dependent antibodies were used for immunoblotting 
as shown above each panel to monitor dephosphorylation of the specific sites of AD P-tau. 102~ (A), Tau-l (B) and SM133 (C) recognize 
dephosphorylated forms, whereas SM131 (D) and PHF-1 (E) recognize phosphorylated forms of tau at specific sites as described in section 2. 
Molecular weight (kDa) markers are indicated at left margin of the figure. SM133, a monoclonal antibody to neurofilament heavy/medium subunits, 
crossreacts with tau unphosphorylated at Ser-235 [I 51. In lane 4, panel C, the 88 kDa protein band stained prominently without a corresponding 
staining in the tau region is probably not tau. 
that in addition to above sites, PP-2B also 
dephosphorylated another abnormal phosphorylation 
site, Ser-235 [22]. In the present study, using im- 
munoblots with five site-specific phosphorylation-de- 
pendent antibodies which recognize six abnormal phos- 
phorylation sites of AD P-tau, we have further examined 
whether PP-1 and PP-2C can also dephosphorylate these 
abnormal phosphorylation sites at optimum in vitro con- 
ditions. PP-2B was employed as a positive control. We 
found that PP-1 unmasked the epitope of antibody Tau-1 
and blocked the epitopes of antibodies SM13 1 and PHF- 
1, but failed to unblock the epitopes of antibodies 102~ 
and SM133 (Fig. 2). PP-2C did not change any of these 
epitopes. These results indicate that PP-1 dephospho- 
rylates abnormal phosphorylation sites Ser-199, Ser-202, 
Ser-396 and Ser-404 but not Ser-46 and Ser-235 of AD 
P-tau. Whereas PP-2C had no effect on dephosphoryla- 
tion of above sites. 
The rate of dephosphorylation of Ser-199/Ser-202, 
Ser-396/Ser-404 and Ser-396 of AD P-tau by PP-1 was 
determined using immunoblots with Tau- 1, SM13 1 and 
PHF-1, respectively. The time course showed a rapid 
change of epitopes of AD P-tau towards these three an- 
tibodies (Fig. 3). Within 20-30 min incubation of AD 
P-tau with PP-1, staining of Tau- 1 became maximal and 
those of both PHF-1 and SM131 disappeared com- 
pletely. These results suggested that the four phosphoryl- 
ation sites of AD P-tau can be easily hydrolyzed by PP- 1. 
We have also investigated the dephosphorylation of 
AD P-tau at various conditions (Fig. 4). In the absence 
of metal (1 .O mM EDTA present), PP-1 could also de- 
phosphorylate AD P-tau at Ser-396 but the activity was 
low. Dephosphorylation of AD P-tau by PP-1 was 
strongly activated by 1.0 mM Mn2+ but inhibited by 10 
mM Mg2+. We further investigated the required concen- 
tration of Mn2’ for this activation. The activation was 
observed at 10 PM Mn2’ and it reached maximum at 
about 100 PM Mn*+ (Fig. 5); the physiological evel of 
Mn*’ is 5-l 1 PM in brain [33]. 
3.3. Dephosphorylation of r3’P]tau by PP-I and PP-2C 
Tau protein is known to be phosphorylated in vitro at 
Ser-214, Ser-324, Ser-356, Ser-409 and Ser-416 by PKA 
[29]. So far none of these sites have been reported to be 
abnormally phosphorylated in Alzheimer disease brain, 
but they may be involved in normal phosphorylation of 
tau. We therefore asked whether these non-abnormal 
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Fig. 3. Time course of dephosphorylation of AD P-tau by PP-1. Im- 
munoblots of AD P-tau were carried out after incubation either without 
(lane 1) or with 1.0 unit/ml PP-1 as described in Fig. 2 at 30°C for 
different time intervals (lanes 2-10). Phosphorylation-dependent anti- 
bodies Tau-l (A), SM131 (B) and PHF-I (C) were used to monitor the 
dephosphorylation. Molecular weight (kDa) markers are indicated at 
the left of each panel. 
C.-X Gong et al. IFEBS Letters 341 (1994) 94-98 
-T I \ I 
0 20 40 60 80 100 120 
Time (min) 
Fig. 4. Effect of Mn*’ and Me on dephosphorylation of AD P-tau by 
PP-1. AD P-tau was incubated with 1 .O unit/ml PP-1 in the presence of 
either 1.0 mM EDTA (0), 1.0 mM Mn” (0) or 10 mM Mg2+ a) at 
30°C for different time intervals as described in section 2. After incuba- 
tion, AD P-tau was subjected to immunoblotting with monoclonal 
antibody PHF-1 which stains only phosphorylated forms of tau, fol- 
lowed by densitometric scanning. Dephosphorylation is expressed by 
percentage of remaining PHF-1 staining. 
phosphorylation sites of tau can be dephosphorylated by 
either PP-1 and PP-2C. Interestingly, even though PP-1, 
PP-2B and PP-2C had obviously different effects on 
dephosphorylation of abnormal phosphorylation sites of 
AD P-tau, they had similar high activities towards 
[32P]tau phosphorylated by PKA (Fig. 6). 
4. Discussion 
In order to examine whether there is a defect of protein 
phosphatase(s) that might be involved in the abnormal 
phosphorylation of tau in AD brain, it is essential to 
identify which protein phosphatase(s) can dephospho- 
rylate the AD P-tau. We have recently found that PP-2A 
and PP-2B rapidly dephosphorylate AD P-tau in vitro 
([22] and Gong et al. manuscript submitted for publica- 
tion). The present study shows that PP-1 also dephos- 
phorylates AD P-tau at some of the sites whereas PP-2C 
has no activity towards any of the sites studied. Although 
three of four types of protein phosphatases can dephos- 
phorylate AD P-tau, they have different site specificities. 
Six of nine known abnormal phosphorylation sites of 
AD P-tau have been examined in these studies. They are 
Ser-46, Ser-199, Ser-202, Ser-235, Ser-396 and Ser-404. 
All of them can be dephosphorylated by PP-2B; PP-2A 
can dephosphorylate all except S-235; and PP-1 dephos- 
phorylates Ser-199, Ser-202, Ser-396 and Ser-404 but nei- 
ther Ser-46 nor Ser-235. Hence at least four abnormal 
phosphorylation sites, Ser-199, Ser-202, Ser-396 and Ser- 
404, can be dephosphorylated by the three enzymes, PP- 
1, PP-2A and PP-2B. These results indicate that the reg- 
ulation of phosphorylation level of tau is very complex 
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and more than one protein phosphatase might be in- 
volved in hyperphosphorylation of tau in AD. 
When [32P]phosphorylase kinase was used as a sub- 
strate to determine protein phosphatase activities, PP-1 
activity was about 20-fold higher than PP-2C activity in 
human brain extracts [19]. In the present study, also 
using [32P]phosphorylase kinase as a substrate to define 
the activities of both PP-1 and PP-2C, 1 .O unit/ml of PP-1 
almost completely dephosphorylated Ser-199, Ser-202, 
Ser-396 and Ser-404 of AD P-tau in 20-30 min, but 2.0 
units/ml of PP-2C did not dephosphorylate AD P-tau at 
any sites studied at the optimal in vitro conditions. 
Taken together, these results suggest hat AD P-tau is 
not a substrate for PP-2C. 
Tau isolated from adult brain normally contains 2-3 
mol of phosphate per mol of the protein [7-91. However, 
neither the phosphorylation sites nor the responsive ki- 
nase(s) have yet been fully elucidated. Normal tau might 
be partially phosphorylated at Ser-202 and Ser-404 
[31,32], but to date other sites have not been excluded to 
be phosphorylated. PKA is known to phosphorylate tau 
at Ser-214, Ser-234, Ser-356, Ser-409 and Ser-416 [29]. 
PP-2C as well as PP-1 and PP-2B can release about 80% 
radioactivity from PKA-phosphorylated [32P]tau in 60 
min, suggesting that these phosphatases dephospho- 
rylate most of these phosphorylation sites of tau. There- 
fore, even if it is not involved in abnormal phosphoryla- 
tion of Alzheimer tau, PP-2C may be associated with the 
regulation of phosphorylation level of normal tau. 
The present study also shows that PKA- 
phosphorylated tau and AD P-tau serve as different sub- 
strates for protein phosphatases. AD P-tau can be 
dephosphorylated by PP- 1, PP-2A and PP-2B but not by 
loo4 1 
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Fig. 5. Dephosphorylation of AD P-tau by PP-1 at various concentra- 
tions of Mn*‘. AD P-tau was incubated with 1.0 unit/ml PP-1 in the 
presence of various concentrations of MnCl, at 30°C for 60 mm as 
described in section 2. After incubation, AD P-tau was subjected to 
immunoblotting with PHF-1 (which stains only tau phosphorylated at 
Ser-396) followed by densitometric scanning. Dephosphorylation is 
expressed by percentage of remaining PHF-1 staining. 
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Fig. 6. Dephosphorylation of PKA-phosphorylated tau by PP-1, PP-2B 
and PP-2C. PKA-phosphorylated tau (0.1 mg!ml) was incubated either 
without (0) or with 0.4 unit/ml of PP-1 (o), PP-2B (0) or PP-2C (r) 
at 30°C for different time intervals as described in section 2. The 
reaction mixtures also included 1 .O mM MnCl, for PP-1 , 1 .O mM CaCI,, 
1 .O flM calmodulin and 1 .O mM MnCl, for PP-ZB, and 10 mM MgCl, 
for PP-2C. 
PP-2C, whereas PKA-phosphorylated tau is almost an 
equally good substrate for PP-1, PP-2B and PP-2C. 
Whether the completely different behavior of AD P-tau 
and PKA-phosphorylated tau as a substrate for PP-2C 
is due to different phosphorylation sites, and/or due to 
different protein conformations remains to be investi- 
gated. 
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